MedicalResearch.com Interview with:
Lisen Arnheim Dahlström, Associate Professor (Docent)
Institutionen för medicinsk epidemiologi och biostatistik
Department of Medical Epidemiology and Biostatistics
171 77 Stockholm, Sweden
MedicalResearch.com: What are the main findings of the study?
Answer: This is a Swedish/Danish population-based study comparing serious disease outcomes in girls immunized with the quadrivalent HPV vaccine against the unvaccinated population.
The main finding of this study was that none of the 53 outcomes included in the study were more common in the vaccinated population compared to the non-vaccinated population.
MedicalResearch.com: Were any of the findings unexpected?
Answer: Our results were in line with previous studies. However, this was the first population-based study from Europe.
MedicalResearch.com: What should clinicians and patients take away from your report?
Answer: That this study provides evidence that autoimmune conditions, neurological diseases, and thromboembolic disease are not triggered by quadrivalent HPV vaccination.
MedicalResearch.com: What recommendations do you have for future research as a result of this study?
Answer: To continue with population-based monitoring in combination with already existing pharmacovigillance systems.
Arnheim-Dahlström L ,Pasternak B ,Svanström H ,Sparén P ,Hviid A. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ 2013;347:f5906